Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study
Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan, Tung N, Singer CF, Sun P, Lubinski J, Narod SA. Breast Cancer Res Treat. 2016 Jan;155(2):365-73. doi: 10.1007/s10549-016-3685-3. Epub 2016 Jan 16.
These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.
Is menopausal hormone therapy safe when your patient carries a BRCA mutation?
Kaunitz, AM. “Is menopausal hormone therapy safe when your patient carries a BRCA mutation?” OBG Management (2015) Vol. 27, No. 8: 24026.
Use of the systemic hormone therapy in BRCA mutation carriers
Domcheck, S and Kaunitz, A. “Use of the systemic hormone therapy in BRCA mutation carriers.” Menopause: The Journal of The North American Menopause Society (2016) Vol. 23:1026-1027. (May require a subscription for access)